Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27373948 | 0.90 | ERCC1 (0.53) | NOTUMLMNAKDM4EALDH1A1MAPK1 | |
| SCHEMBL5934873 | 0.86 | NOTUM (0.57) | NOTUMLMNAKDM4EALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL6006151 | 0.84 | NOTUM (0.55) | NOTUMLMNAKDM4EALDH1A1MAPK1 | |
| SCHEMBL1507232 | 0.78 | NOTUM (0.64) | NOTUMLMNAKDM4EALDH1A1MAPK1 | |
| SCHEMBL18289088 | 0.77 | ERCC1 (0.51) | NOTUMLMNAKDM4EALDH1A1MAPK1 | |
| SCHEMBL254441 | 0.77 | TP53 (0.49) | NOTUMLMNAKDM4EALDH1A1MAPK1 | |
| SCHEMBL521666 | 0.77 | MAPT (0.52) | NOTUMLMNAKDM4EALDH1A1MAPK1 | |
| SCHEMBL2463180 | 0.77 | NOTUM (0.48) | NOTUMLMNAKDM4EALDH1A1MAPK1 | |
| SCHEMBL20930858 | 0.77 | ERCC1 (0.58) | NOTUMLMNAKDM4EALDH1A1MAPK1 | |
| SCHEMBL173839 | 0.77 | NOTUM (0.63) | NOTUMLMNAKDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114426562-B | Platinum (II) complex containing carboline structure, preparation method and application thereof, and organic photoelectric device | 中国石油化工股份有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-112940045-B | Bivalent platinum complex, preparation method thereof and application thereof in luminescent material | 南京工业大学 | 2022-12-23 | — | — | CN | claimed |
| CN-114426562-A | Platinum (II) complex containing carboline structure, preparation method and application thereof, and organic photoelectric device | 中国石油化工股份有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-101965350-A | Novel pyrazolo [3,4-d ] pyrimidine derivatives as anticancer agents | NATCO PHARMA LTD | 2011-02-02 | — | — | CN | claimed |
| EP-2247596-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | Natco Pharma Limited (IN) | 2010-11-10 | — | — | EP | claimed |
| WO-2009098715-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-08-13 | — | — | WO | claimed |
| CN-114426562-B | Platinum (II) complex containing carboline structure, preparation method and application thereof, and organic photoelectric device | 中国石油化工股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-112940045-B | Bivalent platinum complex, preparation method thereof and application thereof in luminescent material | 南京工业大学 | 2022-12-23 | — | — | CN | disclosed |
| CN-114426562-A | Platinum (II) complex containing carboline structure, preparation method and application thereof, and organic photoelectric device | 中国石油化工股份有限公司 | 2022-05-03 | — | — | CN | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113690-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-105658640-A | Alkynyl alcohols and methods of use | 豪夫迈·罗氏有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | disclosed |
| EP-2283022-B1 | FURO [3, 2-B]PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-07-18 | — | — | EP | disclosed |
| CN-101965350-A | Novel pyrazolo [3,4-d ] pyrimidine derivatives as anticancer agents | NATCO PHARMA LTD | 2011-02-02 | — | — | CN | disclosed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| EP-2247596-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | Natco Pharma Limited (IN) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009112826-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009098715-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | DPYD, TYMP, TYMS | NOTUM 4462/4885LMNA 4335/4885KDM4E 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.